Allergy Therapeutics (AGY) — Cash Flow Reinvestment Rate
Allergy Therapeutics (AGY) has a Cash Flow Reinvestment Rate of 0.31x as of December 2021, reinvesting GBX1.15 Million (capex GBX1.15 Million ) from operating cash flow of GBX3.71 Million. See free cash flow generation of Allergy Therapeutics to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Allergy Therapeutics Cash Flow Reinvestment Rate (2003–2021)
Historical reinvestment intensity for Allergy Therapeutics across 11 annual periods. For the full cash flow conversion analysis, see AGY cash flow metrics.
Annual Cash Flow Reinvestment Rate for Allergy Therapeutics (2003–2021)
Year-by-year capital reinvestment analysis for Allergy Therapeutics. See AGY financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (GBX) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 0.61x | GBX5.20 Million | GBX8.52 Million | GBX2.56 Million | ▲ +48.3% |
| 2020 | 0.41x | GBX5.06 Million | GBX12.28 Million | GBX2.55 Million | ▼ -62.6% |
| 2019 | 1.10x | GBX6.16 Million | GBX5.60 Million | GBX2.81 Million | ▼ -94.3% |
| 2017 | 19.34x | GBX3.44 Million | GBX178.00K | GBX1.50 Million | ▲ +5436.9% |
| 2015 | 0.35x | GBX1.09 Million | GBX3.12 Million | GBX1.09 Million | ▼ -15.5% |
| 2014 | 0.41x | GBX898.00K | GBX2.17 Million | GBX898.00K | ▲ +22.4% |
| 2013 | 0.34x | GBX821.00K | GBX2.43 Million | GBX821.00K | ▼ -22.9% |
| 2012 | 0.44x | GBX1.26 Million | GBX2.88 Million | GBX1.26 Million | ▼ -56.1% |
| 2010 | 1.00x | GBX1.70 Million | GBX1.70 Million | GBX1.70 Million | ▲ +150.2% |
| 2004 | 0.40x | GBX760.00K | GBX1.91 Million | GBX760.00K | ▲ +105.8% |
| 2003 | 0.19x | GBX406.00K | GBX2.10 Million | GBX406.00K | — |